CA2400929C - Agents de liaison selectifs antagonistes de proteine de liaison d'osteoprotegerine - Google Patents

Agents de liaison selectifs antagonistes de proteine de liaison d'osteoprotegerine Download PDF

Info

Publication number
CA2400929C
CA2400929C CA2400929A CA2400929A CA2400929C CA 2400929 C CA2400929 C CA 2400929C CA 2400929 A CA2400929 A CA 2400929A CA 2400929 A CA2400929 A CA 2400929A CA 2400929 C CA2400929 C CA 2400929C
Authority
CA
Canada
Prior art keywords
ser
opgbp
gly
seq
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2400929A
Other languages
English (en)
Other versions
CA2400929A1 (fr
Inventor
Rajendra V. Deshpande
Anna Hitz
William J. Boyle
John Kevin Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27057130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2400929(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/791,153 external-priority patent/US20030103978A1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA2400929A1 publication Critical patent/CA2400929A1/fr
Application granted granted Critical
Publication of CA2400929C publication Critical patent/CA2400929C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des agents de liaison sélectifs de protéine de liaison d'ostéoprotégérine (OPGbp). Plus particulièrement, cette invention concerne des domaines de liaison d'anticorps et d'antigènes qui se fixent sélectivement sur les OPGbp et qui peuvent être utilisés pour prévenir ou traiter les états liées à la perte de la masse osseuse. En outre, cette invention concerne des molécules d'acide nucléique codant ces domaines de liaison d'anticorps et d'antigènes, ainsi que les vecteurs d'expression et les cellules hôtes utilisés dans leur production.
CA2400929A 2000-02-23 2001-02-23 Agents de liaison selectifs antagonistes de proteine de liaison d'osteoprotegerine Expired - Lifetime CA2400929C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51113900A 2000-02-23 2000-02-23
US09/511,139 2000-02-23
US09/791,153 US20030103978A1 (en) 2000-02-23 2001-02-22 Selective binding agents of osteoprotegerin binding protein
US09/791,153 2001-02-22
PCT/US2001/005973 WO2001062932A1 (fr) 2000-02-23 2001-02-23 Agents de liaison selectifs antagonistes de proteine de liaison d'osteoprotegerine

Publications (2)

Publication Number Publication Date
CA2400929A1 CA2400929A1 (fr) 2001-08-30
CA2400929C true CA2400929C (fr) 2011-05-31

Family

ID=27057130

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2400929A Expired - Lifetime CA2400929C (fr) 2000-02-23 2001-02-23 Agents de liaison selectifs antagonistes de proteine de liaison d'osteoprotegerine

Country Status (9)

Country Link
EP (1) EP1257648B2 (fr)
JP (1) JP4401613B2 (fr)
AU (1) AU3868001A (fr)
CA (1) CA2400929C (fr)
DE (1) DE60134459D1 (fr)
DK (1) DK2105449T3 (fr)
MX (1) MXPA02008144A (fr)
SI (1) SI1257648T2 (fr)
WO (1) WO2001062932A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
ES2284203T5 (es) 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU762574B2 (en) 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
WO2002024896A2 (fr) 2000-09-22 2002-03-28 Immunex Corporation Methode de criblage d'agonistes ou d'antagonistes de l'activateur du recepteur de nf-kb
EP2295081B1 (fr) 2001-06-26 2018-10-31 Amgen Inc. Anticorps OPGL
DE10210427A1 (de) * 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Humaner monoklonaler Antikörper
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
EP1521776A2 (fr) 2002-07-04 2005-04-13 Oncomab Gmbh Anticorps specifiques de neoplasme et utilisations associees
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
CA2523912A1 (fr) 2003-04-30 2004-11-11 Japan Science And Technology Agency Anticorps humain d'interleukine-18 antihumaine, fragment de celle-ci et procede d'utilisation correspondant
WO2005030793A2 (fr) 2003-09-24 2005-04-07 Millennium Pharmaceuticals, Inc. Anticorps se liant aux cxcr3 humains
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (fr) 2003-11-14 2005-05-18 Heinz Vollmers Anticorps SAM-6, spécifique d'adénocarcinome, et ses utilisations
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
WO2006004988A2 (fr) * 2004-06-30 2006-01-12 Mayo Foundation For Medical Education And Research Anticorps se liant a b7-dc
US7501119B2 (en) 2004-06-30 2009-03-10 Mayo Foundation For Medical Education And Research Methods and molecules for modulating an immune response
EP3030249B1 (fr) 2013-08-07 2019-12-25 Rigshospitalet, Copenhagen University Hospital Anticorps, composés et dérivés associés destinés à être utilisés dans le traitement de l'infertilité masculine
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
WO2019213551A1 (fr) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Méthodes de traitement de la toxicomanie
AU2023329315A1 (en) 2022-08-24 2025-01-16 Amgen Inc. Anti-drug antibody assays

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1114864E (pt) † 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
DE69740107D1 (de) † 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
ES2263204T5 (es) † 1997-04-15 2013-10-14 Daiichi Sankyo Company, Limited Nueva proteína y proceso para producir la misma
ES2284203T5 (es) † 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
HUP0103578A3 (en) † 1998-09-15 2005-11-28 Pharmexa As Method for down-regulating osteoprotegerin ligand activity

Also Published As

Publication number Publication date
EP1257648A1 (fr) 2002-11-20
JP2003523772A (ja) 2003-08-12
EP1257648B2 (fr) 2016-09-14
SI1257648T2 (sl) 2016-11-30
WO2001062932A1 (fr) 2001-08-30
DK2105449T3 (da) 2019-10-07
DE60134459D1 (de) 2008-07-31
AU3868001A (en) 2001-09-03
JP4401613B2 (ja) 2010-01-20
CA2400929A1 (fr) 2001-08-30
EP1257648B1 (fr) 2008-06-18
MXPA02008144A (es) 2002-11-29

Similar Documents

Publication Publication Date Title
EP2330197B1 (fr) Agents antagonistes de liaison sélective de protéine de liaison d'ostéoprotégérine
CA2400929C (fr) Agents de liaison selectifs antagonistes de proteine de liaison d'osteoprotegerine
AU2001238680B2 (en) Antagonistic selective binding agents of osteoprotegerin binding protein
DE DK et al. Thousand Oaks, CA 91320-1799 (US)
DE DK et al. Designated Extension States
DE DK et al. ANTAGONISTISCHE SELEKTIVE BINDUNGSAGENZIEN DES OSTEOPROTEGERIN-BINDUNGSPROTEINS AGENTS DE LIAISON SELECTIFS ANTAGONISTES DE PROTEINE DE LIAISON D’OSTEOPROTEGERINE
AU2001238680A1 (en) Antagonistic selective binding agents of osteoprotegerin binding protein
HK1136308A (en) Antagonistic selective binding agents of osteoprotegerin binding protein
HK1158696B (en) Antagonistic selective binding agents of osteoprotegerin binding protein
HK1136308B (en) Antagonistic selective binding agents of osteoprotegerin binding protein
CA2502668C (fr) Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210223